Author Archives: abcuro

ProBioGen and Abcuro sign GlymaxX®-Improved Cell Line Development and GMP Production Agreement

Berlin, Germany, May 23rd, 2019 ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, … Read More

Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target KLRG1…

Antibody blockade induces anticancer response in solid tumor models. First in vivo validation of KLRG1 as a cancer immunotherapy target. KLRG1 is a driver of adaptive resistance to immunotherapy in humans. NEWTON, Mass., March 26, 2019 /PRNewswire/ — Abcuro, Inc., a biopharmaceutical … Read More


This financing will advance the preclinical development of their programs in autoimmunity and immuno-oncology. Cambridge, MA – Abcuro, a leading biotechnology company focused on immunology therapeutics, announced the completion of a $8M Series A financing round.  Partners Innovation Fund, Kaitai … Read More